Hansoh Pharmaceutical’s Olatorepatide GLP-1/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s National Medical Products Administration (NMPA)...
Johnson & Johnson’s Nipocalimab (Imaavy) Demonstrates Efficacy in Phase II JASMINE Study for Systemic Lupus Erythematosus, First FcRn Blocker to Show Success in SLE
Johnson & Johnson (J&J, NYSE: JNJ) announced positive results from the Phase II JASMINE study...
Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery
H. Lundbeck A/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle,...
Medtronic Makes Strategic ICE Catheter Investments to Strengthen Cardiac Ablation Leadership and Affera Ecosystem Integration
Medtronic plc (NYSE: MDT) announced on June 3, 2026, strategic investments in two privately held...
Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has significantly expanded its collaboration with fellow US biotechnology company...
Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases
Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research...
Medtronic Submits FDA 510(k) Filings to Expand Hugo RAS System into General and Gynecologic Surgery, Adds LigaSure Maryland Instrument
Medtronic plc (NYSE: MDT) announced on June 3, 2026, the submission of 510(k) premarket notifications...
Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market
Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced...
Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical...
Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%
Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year...
FDA Issues Draft Guidance to Accelerate Gene Therapy Development Through Platform Knowledge Sharing
The U.S. Food and Drug Administration (FDA) released draft guidance on June 2, 2026, designed...
China’s National Health Commission Unveils Ambitious Plan for Community Health Service Expansion by 2030
China’s National Health Commission (NHC) has released the “Notice on Further Improving the Urban Community...
Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical...
Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China
Wuhan Kadwise Biotechnology Co., Ltd., a China-based gynecologic oncology specialist with extensive expertise in genetic...
Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations
Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced it has received clinical trial approval from...
Genesis MedTech Secures CE Mark for World’s First Integrated Scissor-Type Ultrasonic Scalpel, Following 2025 China Approval
Genesis MedTech, a Singapore-based medical device innovator, announced it has received CE Mark certification for...
Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market
Everest Medicines (HKG: 1952) announced a strategic licensing agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX),...
Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World’s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule
Signet Therapeutics, an AI-driven biotechnology company incubated by Xtalpi Inc. (HKG: 2228), announced it has...
Legend Biotech’s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed/Refractory B-Cell Lymphoma with No Serious Safety Events
Legend Biotech Corporation (NASDAQ: LEGN) announced preliminary clinical data for LB2501, its investigational first-in-class CD19/CD20...